Our Company

Dr Brandon Howard

Chief Clinical Officer

Dr. Howard has been in the pharmaceutical industry for 20 years with increasing responsibilities in Medical Affairs strategy and leadership as well as spearheading large Clinical Development programs.

She was previously Head of Medical and Clinical Affairs at Evofem Biosciences since 2016 where she led the clinical program for the FDA approval of Phexxi® as well as the creation of the Medical Affairs organization in support of the launch. She was also responsible for driving the successful Phase 2b/3 study for additional indications and the current Phase 3 confirmatory trial. Prior to joining Evofem, she spent eight years in various roles at Teva Pharmaceuticals in Global and U.S. Medical Affairs, including being the Head of U.S. Field Medical Affairs directing over 100 Medical Affairs professionals across 8 therapeutic areas and the U.S. Medical Director for Women’s Health. She also has extensive knowledge in the Women’s Health space including investor relations and business development. Her Ph.D. research at the University of Pennsylvania focused on adolescent sexual behaviors and contraceptive use.

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue